Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 17649
Country/Region: Uganda
Year: 2016
Main Partner: University Research Corporation, LLC
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $11,408,310 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,219,234
Care: TB/HIV (HVTB) $525,157
Care: Pediatric Care and Support (PDCS) $704,254
Laboratory Infrastructure (HLAB) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $990,888
Testing: HIV Testing and Counseling (HVCT) $1,159,824
Sexual Prevention: Other Sexual Prevention (HVOP) $589,042
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $406,320
Treatment: Adult Treatment (HTXS) $4,580,276
Treatment: Pediatric Treatment (PDTX) $233,315
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 269
GEND_GBV Age/Sex: <10 Female 2017 163
GEND_GBV Age/Sex: <10 Male 2017 153
GEND_GBV Age/Sex: <10 Male 2017 99
GEND_GBV Age/Sex: 10-14 Female 2017 745
GEND_GBV Age/Sex: 10-14 Female 2017 463
GEND_GBV Age/Sex: 10-14 Male 2017 153
GEND_GBV Age/Sex: 10-14 Male 2017 99
GEND_GBV Age/Sex: 15-19 Female 2017 1,325
GEND_GBV Age/Sex: 15-19 Female 2017 830
GEND_GBV Age/Sex: 15-19 Male 2017 274
GEND_GBV Age/Sex: 15-19 male 2017 162
GEND_GBV Age/Sex: 20-24 Female 2017 1,311
GEND_GBV Age/Sex: 20-24 Female 2017 823
GEND_GBV Age/Sex: 20-24 Male 2017 269
GEND_GBV Age/Sex: 20-24 Male 2017 163
GEND_GBV Age/Sex: 25-49 Female 2017 537
GEND_GBV Age/Sex: 25-49 Female 2017 335
GEND_GBV Age/Sex: 25-49 Male 2017 269
GEND_GBV Age/Sex: 25-49 Male 2017 163
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 473
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 298
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 1,169
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 726
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 4,136
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 2,574
GEND_GBV Number of people receiving post-GBV care 2017 5,305
GEND_GBV Number of people receiving post-GBV care 2017 3,300
GEND_GBV Sum of Age/Sex Disaggregates 2017 1,320
GEND_GBV Sum of Age/Sex Disaggregates 2017 824
HTS_TST Age/sex: <1 2017 3,230
HTS_TST Age/sex: <1 2017 4,226
HTS_TST Age/sex: 1-9 2017 10,659
HTS_TST Age/sex: 1-9 2017 13,923
HTS_TST Age/sex: 10-14 Female 2017 12,004
HTS_TST Age/sex: 10-14 Female 2017 9,208
HTS_TST Age/sex: 10-14 Male 2017 12,015
HTS_TST Age/sex: 10-14 Male 2017 9,202
HTS_TST Age/sex: 15-19 Female 2017 42,245
HTS_TST Age/sex: 15-19 Female 2017 31,135
HTS_TST Age/sex: 15-19 Male 2017 34,303
HTS_TST Age/sex: 15-19 Male 2017 38,501
HTS_TST Age/sex: 20-24 Female 2017 63,369
HTS_TST Age/sex: 20-24 Female 2017 46,703
HTS_TST Age/sex: 20-24 Male 2017 51,459
HTS_TST Age/sex: 20-24 Male 2017 57,755
HTS_TST Age/sex: 25-49 Female 2017 97,165
HTS_TST Age/sex: 25-49 Female 2017 71,610
HTS_TST Age/sex: 25-49 Male 2017 78,892
HTS_TST Age/sex: 25-49 Male 2017 88,557
HTS_TST Age/sex: 50+ Female 2017 8,445
HTS_TST Age/sex: 50+ Female 2017 6,223
HTS_TST Age/sex: 50+ Male 2017 6,846
HTS_TST Age/sex: 50+ Male 2017 7,701
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 16,153
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 21,075
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 16,146
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 21,093
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 155,671
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 211,224
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 192,514
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 171,500
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 424,892
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 380,484
HTS_TST Service Delivery Point (Facility): Index testing 2017 15,437
HTS_TST Service Delivery Point (Facility): Index testing 2017 15,990
HTS_TST Service Delivery Point (Facility): Inpatient 2017 57,013
HTS_TST Service Delivery Point (Facility): Inpatient 2017 65,245
HTS_TST Service Delivery Point (Facility): Other PITC 2017 19,718
HTS_TST Service Delivery Point (Facility): Other PITC 2017 23,231
HTS_TST Service Delivery Point (Facility): Outpatient 2017 124,841
HTS_TST Service Delivery Point (Facility): Outpatient 2017 159,416
HTS_TST Service Delivery Point (Facility): Pediatric 2017 30,752
HTS_TST Service Delivery Point (Facility): Pediatric 2017 39,854
HTS_TST Service Delivery Point (Facility): PMTCT 2017 57,856
HTS_TST Service Delivery Point (Facility): PMTCT 2017 92,887
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,468
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 2,671
HTS_TST Service Delivery Point (Facility): VMMC 2017 72,399
HTS_TST Service Delivery Point (Facility): VMMC 2017 25,598
HTS_TST Sum of Age/Sex disaggregates 2017 406,743
HTS_TST Sum of Age/Sex disaggregates 2017 366,595
HTS_TST Sum of Aggregated Age/Sex <15 2017 32,299
HTS_TST Sum of Aggregated Age/Sex <15 2017 42,168
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 348,185
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 382,724
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 380,484
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 424,892
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 325
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 288
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 332
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 287
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 1,041
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 843
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 624
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 742
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,568
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 1,265
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 936
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 1,117
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 2,387
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 1,935
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,430
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,706
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 200
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 169
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 123
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 147
HTS_TST_POS Test Result by Age: Positive: <1 2017 98
HTS_TST_POS Test Result by Age: Positive: <1 2017 98
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 331
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 370
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 503
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 556
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 501
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 569
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 4,212
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 5,196
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3,712
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 3,113
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 5,284
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 5,284
KP_PREV Total estimated number of key population in the catchment area 2017 7,829
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 7,829
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,621
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,091
PMTCT_ART New on ART 2017 1,170
PMTCT_ART New on ART 2017 785
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 94,474
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 58,807
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,845
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,234
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 506
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 336
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 9
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 11
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 89
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 59
PMTCT_EID Sum of Infant Age disaggregates 2017 2,351
PMTCT_EID Sum of Infant Age disaggregates 2017 1,570
PMTCT_STAT By: Known positives at entry 2017 1,559
PMTCT_STAT By: Known positives at entry 2017 1,026
PMTCT_STAT By: Number of new positives identified 2017 1,376
PMTCT_STAT By: Number of new positives identified 2017 944
PMTCT_STAT Number of new ANC and L&D clients 2017 96,898
PMTCT_STAT Number of new ANC and L&D clients 2017 60,313
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 94,474
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 58,807
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,935
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,970
PP_PREV Aggregated Age/sex: <15 Female 2017 10,970
PP_PREV Aggregated Age/sex: <15 Male 2017 10,125
PP_PREV Aggregated Age/sex: 15+ Female 2017 12,877
PP_PREV Aggregated Age/sex: 15+ Male 2017 12,910
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 46,882
PP_PREV Total number of people in the target population 2017 199,713
PrEP_NEW Female 15-19 2017 66
PrEP_NEW Female 20-24 2017 30
PrEP_NEW Female 25-49 2017 18
PrEP_NEW Female 50+ 2017 2
PrEP_NEW Male 15-19 2017 50
PrEP_NEW Male 20-24 2017 14
PrEP_NEW Male 25-49 2017 18
PrEP_NEW Male 50+ 2017 2
PrEP_NEW Number of adult women and adolecent girls newly enrolled on oral or topical PrEP 2017 200
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 91
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 138
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 5
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 215
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 274
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 308
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 419
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 308
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 419
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 4,588
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 3,458
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert) 2017 340
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 455
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 1,043
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 1,379
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,075
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 2,754
TB_SCREENDX Screen Result: Screened Positive for TB 2017 1,148
TB_SCREENDX Screen Results: Screened Positive for TB 2017 869
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 1,449
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 1,278
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 26,741
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 35,465
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 13,776
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 18,264
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,904
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 1,690
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 43,244
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 57,323
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 22
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 37
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 417
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 517
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 32
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 49
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 776
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 936
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,247
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,539
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,247
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,539
TX_CURR Age/Sex: <1 2017 93
TX_CURR Age/Sex: <1 2017 138
TX_CURR Age/Sex: <1-9 2017 869
TX_CURR Age/Sex: 1-9 2017 671
TX_CURR Age/Sex: 10-14 Female 2017 1,055
TX_CURR Age/Sex: 10-14 Female 2017 1,389
TX_CURR Age/Sex: 10-14 Male 2017 908
TX_CURR Age/Sex: 10-14 Male 2017 1,198
TX_CURR Age/Sex: 15-19 Female 2017 1,338
TX_CURR Age/Sex: 15-19 Female 2017 1,776
TX_CURR Age/Sex: 15-19 Male 2017 411
TX_CURR Age/Sex: 15-19 Male 2017 547
TX_CURR Age/Sex: 20-24 Female 2017 6,147
TX_CURR Age/Sex: 20-24 Female 2017 8,155
TX_CURR Age/Sex: 20-24 Male 2017 2,751
TX_CURR Age/Sex: 20-24 Male 2017 3,650
TX_CURR Age/Sex: 25-49 Female 2017 17,918
TX_CURR Age/Sex: 25-49 Female 2017 23,758
TX_CURR Age/Sex: 25-49 Male 2017 9,920
TX_CURR Age/Sex: 25-49 Male 2017 13,153
TX_CURR Age/Sex: 50+ Female 2017 1,338
TX_CURR Age/Sex: 50+ Female 2017 1,776
TX_CURR Age/Sex: 50+ Male 2017 694
TX_CURR Age/Sex: 50+ Male 2017 914
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,449
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,904
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,278
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,690
TX_CURR Aggregated Age/Sex: 15+ Female 2017 26,741
TX_CURR Aggregated Age/Sex: 15+ Female 2017 35,465
TX_CURR Aggregated Age/Sex: 15+ Male 2017 13,776
TX_CURR Aggregated Age/Sex: 15+ Male 2017 18,264
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 43,244
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 57,323
TX_CURR Sum of age/sex disaggregates 2017 2,323
TX_CURR Sum of Age/Sex disaggregations 2017 1,749
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,727
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,594
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 40,517
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 53,729
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 43,244
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 57,323
TX_NEW Aggregated Grouping by Age: <1 2017 23
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 446
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 492
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 389
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 439
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 7,101
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 7,059
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,640
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,634
TX_NEW By Age/Sex: <1 2017 33
TX_NEW By Age/Sex: 1-9 2017 198
TX_NEW By Age/Sex: 1-9 2017 221
TX_NEW By Age/Sex: 10-14 Female 2017 338
TX_NEW By Age/Sex: 10-14 Female 2017 367
TX_NEW By Age/Sex: 10-14 Male 2017 276
TX_NEW By Age/Sex: 10-14 Male 2017 310
TX_NEW By Age/Sex: 15-19 Female 2017 359
TX_NEW By Age/Sex: 15-19 Female 2017 353
TX_NEW By Age/Sex: 15-19 Male 2017 103
TX_NEW By Age/Sex: 15-19 Male 2017 110
TX_NEW By Age/Sex: 20-24 Female 2017 1,630
TX_NEW By Age/Sex: 20-24 Female 2017 1,622
TX_NEW By Age/Sex: 20-24 Male 2017 730
TX_NEW By Age/Sex: 20-24 Male 2017 729
TX_NEW By Age/Sex: 25-49 Female 2017 4,758
TX_NEW By Age/Sex: 25-49 Female 2017 4,730
TX_NEW By Age/Sex: 25-49 Male 2017 2,620
TX_NEW By Age/Sex: 25-49 Male 2017 2,619
TX_NEW By Age/Sex: 50+ Female 2017 354
TX_NEW By Age/Sex: 50+ Female 2017 354
TX_NEW By Age/Sex: 50+ Male 2017 187
TX_NEW By Age/Sex: 50+ Male 2017 176
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 11,576
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 11,624
TX_NEW Sum of Age/Sex disaggregates 2017 11,355
TX_NEW Sum of Age/Sex disaggregates 2017 11,370
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 11,576
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 11,624
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 34,596
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 45,859
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 31,139
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 41,271
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,041
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,369
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 920
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,216
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 19,246
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 25,527
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 9,932
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 13,159
TX_PVLS Numerator: Indication: Routine 2017 31,139
TX_PVLS Numerator: Indication: Routine 2017 41,271
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,162
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,525
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,020
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,354
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 21,389
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 28,365
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 11,025
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 14,615
TX_PVLS_den Denominator: Indication: Routine 2017 34,596
TX_PVLS_den Denominator: Indication: Routine 2017 45,859
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 105
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 126
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 176
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 182
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 193
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 194
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 172
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 192
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 221
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 240
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 792
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 880
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 37
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 45
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,556
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,300
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,260
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,786
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 187
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 176
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,791
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,967
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 240
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 219
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 275
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 260
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,815
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,440
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 8,038
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7,309
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 11,228
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 12,368
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 12,617
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 13,897
TX_RET_den Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 18
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 138
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 119
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 202
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 188
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 222
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 203
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 215
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 201
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 271
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 248
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 988
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 893
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,804
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,644
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,872
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,603
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,498
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,917
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 214
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 187
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 455
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 405
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 269
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 237
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 311
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 282
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,289
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,884
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9,028
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 8,214
VMMC_CIRC By Age: 10-14 2017 38,217
VMMC_CIRC By Age: 15-19 2017 28,417
VMMC_CIRC By Age: 20-24 2017 13,717
VMMC_CIRC By Age: 25-29 2017 7,839
VMMC_CIRC By Age: 30-49 2017 7,839
VMMC_CIRC By Age: 50+ 2017 1,968
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 97,997
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 97,997
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 97,997
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 82,319
Cross Cutting Budget Categories and Known Amounts Total: $575,059
Key Populations: MSM and TG $143,765
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Key Populations: Sex Workers $143,765
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Gender: Gender Based Violence (GBV) $287,529
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building